Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill Covid-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as the company assesses the plasma-based treatment in a Phase III study.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration approved an oral treatment from Roche Holding AG and PTC Therapeutics Inc. for spinal muscular atrophy in adults and children two months and above.
Shares of Biogen jumped more than 11 percent after the company announced the U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
Days after reports of Novavax Inc.’s experimental Covid-19 vaccine candidate producing antibodies in healthy patients in a clinical study, the company announced a license agreement with Serum Institute of India Private Limited (SIPL) to develop up to 1 billion doses of the preventative drug in India and other countries.
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
Pfizer Inc. signed a multi-year agreement to make Gilead Sciences Inc.’s antiviral drug remdesivir in a bid to ramp up supply of the Covid-19 treatment.
The United States Food and Drug Administration approved Bayer’s Lampit (nifurtimox) for use in pediatric patients for the treatment of Chagas disease caused by Trypanosoma cruzi.
The medical cannabis market in the United States, even with all of its restrictions, continues to be a fertile area not only for dispensaries, but pharma companies developing cannabis-derived drugs; and proponents say further growth can be generated by educating physicians about medical cannabis.
While Humira remains the best-selling prescription product worldwide, Keytruda has risen to the No. 2 global rank and is on track to eventually claim the top spot.
In professional sports it is rare for a new franchise to win a championship right away. Not so much these days in pharma. Four members of the launch class of 2018 led their entire categories in sales by the following year